Improvement in hidradenitis suppurativa and quality of life in patients treated with adalimumab: Real‐world results from the HARMONY study
Journal of the European Academy of Dermatology and Venereology Aug 04, 2021
Hafner A, Ghislain PD, Kovács R, et al. - In patients with moderate to severe hidradenitis suppurativa (HS), adalimumab (Humira) treatment led to a decrease in disease severity and improvements in quality of life (QoL) and productivity.
HARMONY (Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting), a multicenter, postmarketing observational study, was conducted.
Rapid (within 12 weeks) and sustained (52 weeks) response to adalimumab was evident.
No report of unexpected safety signals.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
